Akamis Bio
Cambridge, United States · Biotechnology, Genetics, Health Care · 200 employees
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear
Funding history
- Series series a — $60.0M — Dec 2024
- Funding Round — $30.0M — Jan 2023
Recent signals
- Dec 17, 2024: Raised $60.0M in Series series a
- Dec 17, 2024: Akamis Bio Announces $60 Million Funding and Strategic Partnership for NG-350A Development
- Jul 06, 2023: Akamis Bio Strengthens Leadership Team with Key Executive Appointments | BioSpace
- Jan 05, 2023: Raised $30.0M
See plans & pricing → Track Akamis Bio’s funding, hiring, and signals — with verified contacts — on Fundz.